Grants and Contributions

The organization will create a legal clinic for victims of crime bringing an interdisciplinary perspective to the issue of access to justice for victims in criminal matters. The legal clinic will have the dual purpose of providing a legal consultation service for victims of crime and an educational opportunity for undergraduate students studying law and victimology.

Building on stage 1 and 2 of the organization's clinical model, which create safety, stability and address trauma, the stage 3 program will focus on providing survivors with guidance and support, developing stronger connections in their community and further developing their skills and relationships needed to continue their healing journey.

Applications must ensure relevance to all of the following objectives:
• Establish central coordination and collaboration activities with existing clinical trials groups/networks to increase the availability of high-quality and real-time evidence and build capacity to support Canada’s rapid response to the global pandemic and health emergencies in order to better prevent, detect, treat and/or manage COVID-19;
• Establish a transparent, inclusive, multi-jurisdictional recruitment and membership process that describes benefits for and requirements and expectations of members;
• Collaborate across member networks to establish resource and data sharing policies, increase efficiencies in research and related processes (including, but not limited to ethics review; contracts; common protocols; developing applications for trial funding; consistent and valid patient-oriented outcomes), reduce duplication, and maximize research impact for COVID-19;
• Create data sharing agreements to ensure follow-up of patients through existing administrative data platforms within Canada;
• Adopt a nimble and adaptive strategy for engaging stakeholders in research prioritization and oversight while shifting studies as needed, based on new knowledge and changing COVID-19 landscape;
• Provide evidence to inform clinical and health system management and public health response, and/or decision-making and planning within and across jurisdictions in Canada and internationally; and
• Enhance local, national and/or international clinical trial collaborative efforts by aligning clinical trials networks with other COVID-19 research investments to prevent and/or mitigate the rapid spread of COVID-19 and related negative consequences.

.
• To accelerate potential stem cell-based therapies for T1D to the preclinical or clinical trial stage.

The objective of this funding opportunity is to support a knowledge synthesis network designed to collaborate and rapidly respond to the need for synthesized evidence across the full breadth of Canada's COVID-19 pandemic response (including public-health measures, clinical management, health-system arrangements, and economic and social impacts). Through a highly collaborative approach, the knowledge synthesis network is expected to:

-Produce rapid knowledge syntheses and associated evidence-based products (e.g., evidence profiles) related to the COVID-19 pandemic, based on current evidence and that responds to an identified evidence need;
-Provide decision-makers with high-quality, timely, accessible and relevant evidence for the rapid translation of knowledge into policy, practice and/or clinical guidelines to address the immediate response to the pandemic; and
-Address evidence gaps and build the evidence base for the response to COVID-19;
-Enhance national and international coordination across knowledge synthesis experts and organizations involved in producing COVID-19 related products.

.
• To accelerate potential stem cell-based therapies for T1D to the preclinical or clinical trial stage.

Engage consultants for two clinical studies

CytoGnomix Inc is partnering with the Ontario Institute of Evaluative and Clinical Sciences (IC/ES) to obtain access to the geographic COVID-19 daily incidence data and geostatistics software licenses.

BOLD-100 is a first-in-class, clinical-stage investigational therapy being developed for the treatment of patients with cancer and viral infections, including COVID-19.

Project activities include: (1) supporting countries in developing individual RMNCAH-N investment cases to align sources of financing to national priorities; (2) clinical interventions such as increasing access to health services and health facilities from the pre-pregnancy stage onwards for women, newborns and children; (3) health systems interventions such as strengthening health systems, strengthening health information systems and increasing access to medical products/technologies; and (4) multi-sectoral interventions in multiple sectors such as education, nutrition, and water and sanitation and strengthening of CRVS systems.